Search Results

Your search for Jean-Yves Douillard, MD, PhD matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / Monday, June 30, 2014 1:18 PM

Phase III Trial Shows Improved Survival With TAS-102 in Metastatic Colorectal Cancer Refractory to Standard Therapies

The new combination agent TAS-102 can improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona (Abstract O-0022). “Around 50%...

colorectal cancer

By Matthew Stenger / Thursday, September 19, 2013 10:53 AM

Presence of RAS Mutations in Metastatic Colorectal Cancer Predictive of Negative Response to Panitumumab/FOLFOX4 Treatment

Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-EGFR therapy. However, other activating RAS mutations may predict poorer outcome with anti-EGFR therapy. In an analysis reported in The New England Journal of Medicine by Jean-Yves Douillard,...

Apr

Today In Oncology

Search Results

Your search for Jean-Yves Douillard, MD, PhD matches 2 pages

Phase III Trial Shows Improved Survival With TAS-102 in Metastatic Colorectal Cancer Refractory to Standard Therapies

Presence of RAS Mutations in Metastatic Colorectal Cancer Predictive of Negative Response to Panitumumab/FOLFOX4 Treatment

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being